Unmet demand for testosterone in menopause care creates an investable gap — if safety and regulatory questions are solved

Insight first: rising patient-driven use of testosterone for menopause symptoms highlights a clear market need, not yet matched by regulated products or hard evidence outside sexual desire. That imbalance opens multiple venture pathways, but any investment thesis must be grounded in building credible safety data and navigable regulatory strategies.

Why this matters for women and health systems

Testosterone is biologically active in women and declines with age, yet it has been comparatively neglected in female-targeted therapeutic development. For many postmenopausal women, available hormone therapies do not address all symptoms, and clinicians and patients are increasingly turning to testosterone as an adjunct. That trend is altering prescribing patterns and creating pressure on regulators and health services to respond.

Clinical evidence supports a narrow indication: carefully dosed testosterone improves sexual desire in some postmenopausal women, and clinical guidelines recognise it for hypoactive sexual desire disorder. Outside of sexual function, randomized trial data are limited, and observational reports of mood or cognitive benefits remain hypothesis-generating rather than definitive.

Market signals: demand outpacing supply

Prescriptions to women are rising substantially in multiple markets. In England, prescriptions increased roughly tenfold between 2015 and 2022, and in the United States prescribing has nearly tripled over the past decade. Despite this growth, licensed female-specific testosterone products are scarce in many jurisdictions.

Where regulation has moved, the market response remains partial. Australia registered a female-labelled testosterone cream in 2020, and the UK granted marketing authorisation in mid-2025, but routine public access has lagged. The US still lacks an approved female testosterone product and regulators convened a public workshop in September 2026 to examine evidence gaps and development needs.

Key barriers that create investment friction

• Evidence shortfall beyond sexual desire: few long-duration randomized trials evaluating cardiovascular, cerebrovascular, or breast cancer outcomes.
• Measurement problems: routine assays struggle to quantify the low female-range testosterone levels reliably, complicating dosing and monitoring.
• Off-label workarounds: use of male gels at fractionated doses creates dosing variability and safety concerns.
• Regulatory uncertainty: differing approvals and slow reimbursement limit commercial scale in major markets.
• Clinical conservatism: many clinicians want stronger safety data before adopting testosterone broadly, especially for patients at higher baseline risk.

Where investors should look

• Female-specific delivery platforms that enable accurate low-dose transdermal or other targeted administration and reduce transfer risk to partners or children.
• High-sensitivity diagnostic assays and companion monitoring tools that quantify low-range testosterone and support dose titration and safety surveillance.
• Evidence-generation businesses: pragmatic randomized trials, registries, and real-world evidence platforms focused on long-term safety signals in diverse populations.
• Regulatory and market-access services: consultancies and clinical CROs that specialise in endocrine therapies and female-specific regulatory pathways.
• Digital care models and decision-support for clinicians to optimise patient selection, shared decision-making, and adherence monitoring for off-label or novel products.
• Pharmaceutical quality control and compounding standardisation to replace imprecise dosing workarounds with regulated options.

These opportunity areas are complementary. For example, a low-dose delivery device combined with an approved assay and an outcomes registry creates a defensible product-service stack that addresses clinician concerns and payer evidence requirements.

Risks investors must underwrite

• Long-tail safety: absence of large, long-duration trials means cardiovascular and oncologic risk profiles remain incompletely characterised.
• Regulatory reversals: a high-profile adverse signal could trigger label changes, usage restrictions, or reimbursement freezes.
• Off-label reputational risk: firms that appear to encourage broad, non-evidence-based use may face clinical and public backlash.
• Market fragmentation: patchwork approvals and differing national standards complicate scale-up and increase go-to-market costs.
• Litigation exposure: hormone therapies carry elevated medico-legal risk if safety monitoring is inadequate.

Practical due diligence checklist for investors

• Does the product or service materially reduce dosing uncertainty or measurement error for women?
• Is there a credible plan and budget for evidence generation that addresses the safety endpoints regulators care about?
• Are the founders and clinical advisors experienced in sex-specific endocrinology and in navigating female-focused regulatory pathways?
• Does the commercial model account for fragmented reimbursement and need for specialist prescriber engagement?
• What is the post-market surveillance plan to detect and respond to rare but serious adverse outcomes?

Investors should prioritise asset classes that allow staged de-risking: early wins in diagnostics or formulation technology can fund larger, multicentre safety studies that unlock broader indications and payer coverage.

Near-term catalysts to monitor

• Regulatory guidance or approvals for female-labelled testosterone products in major markets, particularly the US.
• Publication of longer-term cohort or randomized data addressing cardiovascular and breast safety.
• Launch of validated low-range testosterone assays and their adoption in clinical practice.
• Changes in public payer policies or reimbursement pathways that recognise testosterone-related indications for women.
• New clinical guideline updates that expand or restrict recommendations for testosterone use in menopause care.

Conclusion: the market signal is clear. Patient demand and rising prescriptions show an unmet need. The path to a durable, scalable market requires products and evidence tailored to women, robust monitoring tools, and regulatory strategy. For investors who can underwrite the time and cost of safety-focused development, this sub-sector offers differentiated returns alongside meaningful clinical impact.